Hanmi Pharm. Co., Ltd. (CEO: Gwan Sun Lee) and Novartis Korea Ltd. (CEO: Brian Gladsden) announced that following the Seoul Symposium on August 26th at Lotte Hotel, they will be holding consecutive symposiums in eight cities countrywide, including Gwangju, Daegu and Busan.

The Seoul Symposium was a success, with 350 doctors participated to discuss Galvus’ advantages as well as the latest trends in regulating blood sugar levels in type-2 diabetes patients.

Chairman of Korean Physicians’ Association, Myung Hee Lee emceed the event as the senior person present, following presentations by Dr. Jong Chul Won (Inje University College of Medicine) on ‘Differentiated effects of vildagliptin in DPP-4 inhibitors’ and Dr. Se Eun Park (Sung Kyun Kwan University School of Medicine) on ‘Clinical cases of regulating target blood sugar levels in diabetes patients.’

“Galvus is an excellent treatment proved effective in lowering hemoglobin A1c, with low hypoglycemia manifestation rate not only in senior patients but also various patient groups for the past five years,” said Myung Hee Lee. “Galvus Met, a combination of DPP-4 and metformin, is also a superb choice in treating type-2 diabetes patients.

Meanwhile, Galvus is a DPP-4 inhibitor therapy for type-2 diabetes, regulating blood sugar levels by inhibiting the breakdown of incretin, a hormone that stimulates the secretion of insulin in the pancreas. Galvus Met is a single-pill fixed-dose combination of Galvus (vildagliptin) and metformin for treatment of diabetes. Hanmi Pharm. Co., Ltd. and Novartis Korea Ltd. have been co-marketing Galvus and Galvus Met since last July.